Compile Data Set for Download or QSAR
maximum 50k data
Found 65 Enz. Inhib. hit(s) with Target = 'RAF proto-oncogene serine/threonine-protein kinase [1-324]'
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202665(US10245267, Example 10 | US10709712, Example 10 | ...)
Affinity DataIC50:  0.118nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202665(US10245267, Example 10 | US10709712, Example 10 | ...)
Affinity DataIC50:  0.118nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202665(US10245267, Example 10 | US10709712, Example 10 | ...)
Affinity DataIC50:  0.120nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202697(US10245267, Example 42 | US10709712, Example 43 | ...)
Affinity DataIC50:  0.137nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202696(US10245267, Example 43 | US10709712, Example 42 | ...)
Affinity DataIC50:  0.137nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202696(US10245267, Example 43 | US10709712, Example 42 | ...)
Affinity DataIC50:  0.140nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202656(US10245267, Example 1 | US10709712, Example 1 | US...)
Affinity DataIC50:  0.140nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202656(US10245267, Example 1 | US10709712, Example 1 | US...)
Affinity DataIC50:  0.144nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202656(US10245267, Example 1 | US10709712, Example 1 | US...)
Affinity DataIC50:  0.144nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202772(US10245267, Example 119 | US10709712, Example 119 ...)
Affinity DataIC50:  0.270nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202772(US10245267, Example 119 | US10709712, Example 119 ...)
Affinity DataIC50:  0.270nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202772(US10245267, Example 119 | US10709712, Example 119 ...)
Affinity DataIC50:  0.270nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202771(US10245267, Example 118 | US10709712, Example 118 ...)
Affinity DataIC50:  0.308nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202771(US10245267, Example 118 | US10709712, Example 118 ...)
Affinity DataIC50:  0.308nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202771(US10245267, Example 118 | US10709712, Example 118 ...)
Affinity DataIC50:  0.310nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202696(US10245267, Example 43 | US10709712, Example 42 | ...)
Affinity DataIC50:  0.376nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202697(US10245267, Example 42 | US10709712, Example 43 | ...)
Affinity DataIC50:  0.376nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202718(US10245267, Example 111 | US10709712, Example 111 ...)
Affinity DataIC50:  0.400nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202718(US10245267, Example 111 | US10709712, Example 111 ...)
Affinity DataIC50:  0.403nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202764(US10245267, Example 64 | US10709712, Example 64 | ...)
Affinity DataIC50:  0.403nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202661(US10245267, Example 6 | US10709712, Example 6 | US...)
Affinity DataIC50:  0.408nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202661(US10245267, Example 6 | US10709712, Example 6 | US...)
Affinity DataIC50:  0.408nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202661(US10245267, Example 6 | US10709712, Example 6 | US...)
Affinity DataIC50:  0.410nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202845(US10245267, Example 198 | US10709712, Example 198 ...)
Affinity DataIC50:  0.455nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202845(US10245267, Example 198 | US10709712, Example 198 ...)
Affinity DataIC50:  0.455nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202845(US10245267, Example 198 | US10709712, Example 198 ...)
Affinity DataIC50:  0.460nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202717(US10245267, Example 63 | US10709712, Example 63 | ...)
Affinity DataIC50:  0.508nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202717(US10245267, Example 63 | US10709712, Example 63 | ...)
Affinity DataIC50:  0.508nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202663(US10709712, Example 8 | US9242969, 8 | US9242969, ...)
Affinity DataIC50:  0.510nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202717(US10245267, Example 63 | US10709712, Example 63 | ...)
Affinity DataIC50:  0.510nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202663(US10709712, Example 8 | US9242969, 8 | US9242969, ...)
Affinity DataIC50:  0.514nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM77059(US10245267, Example 9 | US10709712, Example 9 | US...)
Affinity DataIC50:  0.514nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202668(US10245267, Example 13 | US10709712, Example 13 | ...)
Affinity DataIC50:  0.530nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202668(US10245267, Example 13 | US10709712, Example 13 | ...)
Affinity DataIC50:  0.533nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202668(US10245267, Example 13 | US10709712, Example 13 | ...)
Affinity DataIC50:  0.533nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202666(US10245267, Example 11 | US10709712, Example 11 | ...)
Affinity DataIC50:  0.580nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202666(US10245267, Example 11 | US10709712, Example 11 | ...)
Affinity DataIC50:  0.580nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202666(US10245267, Example 11 | US10709712, Example 11 | ...)
Affinity DataIC50:  0.580nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202843(US10245267, Example 196 | US10709712, Example 196 ...)
Affinity DataIC50:  0.620nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202843(US10245267, Example 196 | US10709712, Example 196 ...)
Affinity DataIC50:  0.621nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202843(US10245267, Example 196 | US10709712, Example 196 ...)
Affinity DataIC50:  0.621nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202698(US10245267, Example 44 | US10709712, Example 44 | ...)
Affinity DataIC50:  0.710nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202698(US10245267, Example 44 | US10709712, Example 44 | ...)
Affinity DataIC50:  0.714nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202698(US10245267, Example 44 | US10709712, Example 44 | ...)
Affinity DataIC50:  0.714nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202669(US10245267, Example 14 | US10709712, Example 14 | ...)
Affinity DataIC50:  0.800nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202669(US10245267, Example 14 | US10709712, Example 14 | ...)
Affinity DataIC50:  0.803nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202669(US10245267, Example 14 | US10709712, Example 14 | ...)
Affinity DataIC50:  0.803nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202764(US10245267, Example 64 | US10709712, Example 64 | ...)
Affinity DataIC50:  0.847nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202718(US10245267, Example 111 | US10709712, Example 111 ...)
Affinity DataIC50:  0.847nMpH: 7.5 T: 2°CAssay Description:Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM202764(US10245267, Example 64 | US10709712, Example 64 | ...)
Affinity DataIC50:  0.850nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 65 total ) | Next | Last >>
Jump to: